DynoChem Extends Software Agreement with Bristol-Myers Squibb
News Jul 11, 2007
The agreement will allow Bristol-Myers Squibb to expand deployment of DynoChem process modeling software throughout its Research and Development group and for scale-up into manufacturing.
Bristol-Myers Squibb noted that in meeting the challenges inherent in the scale-up of synthetic pharmaceutical processes, operation modeling allows the company to make use of knowledge and resources to answer critical questions.
In addition, the incorporation of modeling technologies such as DynoChem across Bristol-Myers Squibb’s process development enterprise helps achieve the company’s development goals.
PFD Managing Director Dr. Joe Hannon said, “We are pleased to have the opportunity to expand our relationship with BMS and continue our commitment to their pharmaceutical product development effort. We believe this agreement further validates DynoChem’s success in achieving our customers’ goals of accelerating process development and lowering drug development costs.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019